{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:47:54Z","timestamp":1760014074665,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.amjcard.2021.11.026","type":"journal-article","created":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T23:05:00Z","timestamp":1640473500000},"page":"127-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril\/Valsartan"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-5192","authenticated-orcid":false,"given":"Tomiko","family":"Sunaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-0217","authenticated-orcid":false,"given":"Yonezawa","family":"Ryo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2021.11.026_bib0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s40800-016-0036-6","article-title":"Rhabdomyolysis after coadministration of atorvastatin and Sacubitril\/Valsartan (Entresto) in a 63-year-old woman","volume":"3","author":"Faber","year":"2016","journal-title":"Drug Saf Case Rep"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0002","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/bcp.13950","article-title":"Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome","volume":"85","author":"Previsdomini","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0003","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.22374\/cjgim.v15i1.343","article-title":"Rhabdomyolysis as a side effect of the drug interaction between atorvastatin and Sacubitril\/valsartan","volume":"15","author":"Chan","year":"2020","journal-title":"Can J Gen Intern Med"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0006","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/pds.3529","article-title":"Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases","volume":"23","author":"Maignen","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF03256796","article-title":"Data mining in drug safety","volume":"24","author":"Deshpande","year":"2010","journal-title":"Pharm Med"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0008","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/14622416.9.1.19","article-title":"Global analysis of genetic variation in SLCO1B1","volume":"9","author":"Pasanen","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0010","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.xphs.2017.01.007","article-title":"Evaluation of drug-drug interaction potential Between Sacubitril\/Valsartan (LCZ696) and statins using a physiologically based pharmacokinetic model","volume":"106","author":"Lin","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.microc.2018.07.021","article-title":"A validated RP-HPLC method for the determination of rosuvastatin in presence of sacubitril\/valsartan in rat plasma: application to in vivo evaluation of OATP-mediated drug interaction potential between rosuvastatin and sacubitril\/valsartan","volume":"143","author":"Moussa","year":"2018","journal-title":"Microchem J"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0012","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/diseases7020038","article-title":"A rare adverse event of rhabdomyolysis caused by Sacubitril\/Valsartan","volume":"7","author":"Rawla","year":"2019","journal-title":"Diseases"},{"key":"10.1016\/j.amjcard.2021.11.026_bib0013","unstructured":"U.S. National Library of Medicine. This study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality of patients with chronic heart failure (PARADIGM-HF). Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01035255. Accessed on August 17, 2021."},{"key":"10.1016\/j.amjcard.2021.11.026_bib0014","unstructured":"U.S. National Library of Medicine. Comparison of Sacubitril\/Valsartan versus enalapril on effect on NT-proBNP in patients stabilized from an acute heart failure episode (Pioneer-HF). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02554890. Accessed on August 17, 2021."},{"key":"10.1016\/j.amjcard.2021.11.026_bib0015","unstructured":"European Medicines Agency. Summary of the risk management plan for Entresto. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/entresto-epar-risk-management-plan-summary_.pdf. Accessed on August 17, 2021."}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914921011541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914921011541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:40:11Z","timestamp":1757572811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914921011541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":15,"alternative-id":["S0002914921011541"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.11.026","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril\/Valsartan","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}